A LANDMARK STUDY. TO ESTABLISH A NEW STANDARD OF CARE.
FOR SELECT HEART FAILURE PATIENTS WITH CLINICALLY SEVERE SECONDARY MITRAL REGURGITATION.
The first and only mitral intervention shown to improve the prognosis of patients with heart failure by reducing secondary mitral regurgitation due to left ventricular dysfunction.
MitraClip® has shown a 47% relative risk reduction in heart failure hospitalizations and a 38% relative risk reduction in mortality through two years. Patients who were treated with MitraClip had significant improvements in quality-of-life and functional capacity during 24-month follow-up compared to guideline directed medical therapy.
COAPT TRIAL RESULTS SUMMARY
LEARN MORE ABOUT MITRAL REGURGITATION:
If you are a patient or a family member of a patient, talk to your physician to learn more about Heart Failure and Secondary MR or visit www.MitraClip.com.